CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50

Background: Chemotherapy resistance is a major problem in breast cancer treatment and a leading cause of mortality in breast cancer patients. Biomarkers for chemotherapy resistance is under investigation. Methods: Paclitaxel resistant cells were established and subjected to RNA sequencing. Analysis...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Theranostics
Glavni autori: Chi, Yayun, Xue, Jingyan, Huang, Sheng, Xiu, Bingqiu, Su, Yonghui, Wang, Wei, Guo, Rong, Wang, Lei, Li, Lun, Shao, Zhiming, Jin, Wei, Wu, Zhaohui, Wu, Jiong
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2019
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815964/
https://ncbi.nlm.nih.gov/pubmed/31660072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.36338
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items